As of today (2024-04-24), Cardiff Oncology's share price is $4.17. Cardiff Oncology's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.56. Hence, Cardiff Oncology's Price to Tangible Book Ratio of today is 2.67.
The historical rank and industry rank for Cardiff Oncology's Price-to-Tangible-Book or its related term are showing as below:
CRDF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59 Med: 2.15 Max: 9.74
Current: 2.67
During the past 13 years, Cardiff Oncology's highest Price to Tangible Book Ratio was 9.74. The lowest was 0.59. And the median was 2.15.
CRDF's Price-to-Tangible-Book is ranked worse than 51.6% of 1221
companies
in the Biotechnology industry
Industry Median: 2.67
vs CRDF: 2.67
A closely related ratio is called PB Ratio. As of today, Cardiff Oncology's share price is $4.17. Cardiff Oncology's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.56. Hence, Cardiff Oncology's P/B Ratio of today is 2.67.
Cardiff Oncology Price-to-Tangible-Book Historical Data
The historical data trend for Cardiff Oncology's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cardiff Oncology Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Cardiff Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiff Oncology (Cardiff Oncology) Business Description
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRDF has been successfully added to your 